Recent studies with very small numbers of patients showed that in some cases of childhood acute lymphoblastic leukemia (ALL), preleukemic cells are detectable on Guthrie cards that were used for newborn screening. We present here the largest series of ALL patients (n ¼ 32) in whom Guthrie cards were analyzed for the presence of preleukemic cells. Rearranged immunoglobulin heavy-chain genes were used as a marker for leukemic clones. We combined our set of patients with 17 previously published cases. Preleukemic cells were detected in 31 of all 49 patients (63%). Positive screening cards were not associated with patient's age at diagnosis but were almost always found in patients with hyperdiploidy (10/11; 91%; P ¼ 0.04). High birth weight is an established risk factor for childhood ALL. Positive screening cards were strongly associated with low birth weight (P ¼ 0.01). In conclusion, the majority of childhood B-precursor ALL arise prior to birth. In the search for causes of childhood leukemia we should concentrate on prenatal factors as well as postnatal factors. Our results suggest that autologous cord bloods could be a poor choice as the source of stem cells for transplantation in leukemia, which may contain preleukemic cells. Pending the development of suitable methods, childhood leukemia is a potentially screenable disease.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Epidemiologic evidence suggests that maternal occupational exposure to extremely low-frequency magnetic fields, 1 maternal use of antihistamines or allergic remedies, 2 central nervous system depressants, 3 the nonsteroidal anti-inflammatory drug dipyrone and mosquitocidals 4 during pregnancy were associated with childhood ALL. In addition, maternal lower genital tract infection during pregnancy significantly increased the risk of childhood leukemia. 5 Further evidence for an in utero leukemic transformation comes from the predominance of fetal type D-J joining of the immunoglobulin H (IgH) heavy-chain genes in young children with B-precursor ALL. 6, 7 The detection of concordant leukemia in monozygotic twins, [8] [9] [10] [11] [12] [13] strongly supports the hypothesis that leukemogenesis may be initiated in utero. The only plausible explanation for concordant leukemia in monozygotic twins is that the transformed cell in one twin spreads to the other twin, presumably by vascular anastomoses that exist within shared monochorionic placentas. 14, 15 Leukemia-specific fusion genes were detected on blood spots of newborn Guthrie cards in a limited number of patients with t(4;11) and t(12;21) translocation. [16] [17] [18] [19] However, only a minority of children with ALL have a detectable leukemiaspecific chromosomal translocation. 20 Therefore, clone-specific antigen receptor gene rearrangements used for the detection of minimal residual disease have been applied in a small number of patients with ALL to investigate the evolution of leukemia. [21] [22] [23] Almost all B-precursor ALLs are characterized by a unique IgH gene rearrangement. 24 This rearrangement varies enormously due to the joining of different variable (V), diversity (D) and joining (J) gene segments. During two successive recombinations, D to J and V to D-J joining, nucleotides can be deleted from the germ-line gene segments by exonuclease activity. In addition, nontemplate-derived nucleotides (N) can be added by the enzyme terminal deoxynucleotidyl transferase. 25 Somatic mutation in any of these gene segments leads to further diversity. 26 This process generates a hypervariable sequence known as complementarity determining region 3 that we have used as a clone-specific marker for the detection of preleukemic clones at birth in 32 children with B-precursor ALL.
We report the largest number of investigated Guthrie cards of children with B-precursor ALL to date. The aim of this study was to determine the frequency of a prenatal origin of B-precursor ALL and to analyze the association of positive Guthrie cards with other patient characteristics.
Patients and methods

Patients
Patients diagnosed with B-precursor ALL, and treated at the Department of Pediatrics, University of Jena, Germany, were eligible for this study. The other criteria for enrollment in this retrospective study included the availability of cryopreserved leukemic bone marrow cells from diagnosis and newborn Guthrie cards. This investigation was approved by the institutional review board, and informed consent was obtained from all patients and their parents, as appropriate. The clinical characteristics of these patients are described in Table 1 . The patients were born between 1982 and 2001 and had a median age at diagnosis of 5 years (range, 15 months to 14 years). There were 17 male and 15 female patients. The median presenting white blood cell (WBC) count was 10150/ml (range, 800-103 800/ ml). A TEL/AML1 rearrangement was present in six patients (patients 6, 11, 13, 18, 22, 23; Table 1 ). Two patients showed a BCR/ABL translocation (patients 1 and 4; Table 1 ) and one patient showed an MLL/AF4 translocation (patient 9; Table 1 ).
DNA extraction, PCR and sequencing
Samples were obtained from diagnostic bone marrow aspirates. Mononuclear cells were purified by Ficoll-Hypaque (Sigma, St Louis, MO, USA) density gradients (density41.077 g/ml) and cryopreserved in liquid nitrogen. At diagnosis, the portion of leukemic cells was greater than 80% of the mononuclear cell in the bone marrow. Genomic DNA was extracted from mononuclear cells using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Amplification of rearranged IgH genes was performed using a universal V H primer complementary to the framework 1 region 27 or framework 2 region 28 together with a universal J H primer. 29 Primers were synthesized on a DNA synthesizer Expedite model 8909 (Perspective Biosystems, Framingham, MA, USA) and purified by high-performance liquid chromatography. Polymerase chain reaction (PCR) was performed using 100 ng DNA and 1.25 units of Taq DNA polymerase (Roche, Mannheim, Germany), in a 50 ml reaction, which contained 
Detection of IgH gene rearrangement
Clone-specific primers complementary to the D-N-J sequence and N-D-N sequence were designed for each patient. The primers were also synthesized on a DNA Synthesizer Expedite model 8909 and purified as described above. A two-stage PCR strategy using a semi-nested approach was performed to achieve high sensitivity and specificity of amplification.
33
PCR was performed using 500 ng DNA and 1.25 units of Taq DNA polymerase (Roche) in a 50 ml reaction, which contained 10 mmol/l Tris-HCL (pH 8. The amplification DNA from the first round was diluted at a ratio of 1:100 and 2 ml of it was used as the template for the second round. The PCR conditions for the second round were the same as described above, except that 45 cycles were performed. We carefully optimized the annealing temperatures in both rounds until we achieved the highest sensitivity and specificity. In both rounds, the V H FR1 family-specific primer specific for the patient rearrangement was used usually with the I H U primer for the first round, and the D-N-J-specific primer or N-D-N-specific primer for the second round. In cases of insufficient sensitivity using the I H U primer for the first round, the D-N-J-specific primer was used for the first round and the N-D-N-specific primer for the second round. PCR products were analyzed by electrophoresis on a 3% Ultra Pure agarose gel (Life Technologies, Gaithersburg, MD, USA).
The sensitivity was established by making serial 10-fold dilutions of leukemic DNA into DNA obtained from pooled peripheral blood mononuclear cells until the PCR product was observed ( Figure 1) . 34 At least three replicates of each dilution were subjected to PCR amplification. Specificity was confirmed using normal peripheral blood DNA and sterile water instead of leukemic DNA as the template in the PCR. To avoid contamination in the PCR amplifications, we followed the procedures recommended by Kwok and Higuchi. 35 
Guthrie card analysis
Guthrie cards prepared from heel sticks of newborns of the children with B-precursor ALL enrolled in this study, were obtained from the Institute of Human Genetics, University of Greifswald, Greifswald, Germany, where they were stored at room temperature up to 25 years. Guthrie card spots were cut into eight pieces and DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen) according to the protocol for isolation of genomic DNA from dried blood. Proteinase K digestion was performed for 12 h at 56 1C to achieve an optimal DNA yield. The ability to amplify extracted DNA was ascertained using primers derived from the second exon of the N-ras gene as previously described. 36 The total amount of the obtained DNA from a Guthrie card spot was determined by N-ras gene PCR using a DNA standard dilution. Semi-nested PCR was performed using clone-specific primers for each patient as described above. PCR products representing rearranged IgH genes, were excised, sequenced and compared to the previously identified IgH sequences of the patient's diagnostic leukemia sample.
The proportion of preleukemic cells on Guthrie cards was calculated by limiting dilution analysis with 24 replicates and Poisson statistics as described by Simmonds et al. 37 and previously used for quantification of minimal residual disease. 33 
Results and discussion
In this study, we analyzed Guthrie cards of 32 children with B-precursor ALL. We enrolled all patients who were treated at the University Children's Hospital Jena and fulfilled the following criteria: diagnosis of B-precursor ALL, availability of newborn screening cards and availability of cryopreserved leukemic cells. Cryopreservation of leukemic cells is a standard procedure in all patients who are diagnosed with leukemia in our hospital.
A two-stage PCR using a semi-nested approach was developed to improve the sensitivity and specificity of amplification of patient/leukemic blast-specific IgH gene rearrangements. Sequencing of the PCR products obtained from Guthrie card blood spots revealed the identical IgH sequences identified from diagnostic leukemic cells.
Dilution experiments confirmed that the sensitivity of the PCR assay detected one leukemic cell in a background of X10 (Table 1 ). In 13 patients it was below 1/10 3 , that is, in the range of the lowest detectable concentration. It is very likely that among the patients with negative screening cards, there are some patients in whom the leukemic cell clone was also present, but below the detectable range of our assay. Hence, the percentage of children with B-precursor ALL in whom preleukemic cell clones are present at birth may be greater than 60% (Figure 2) .
Taub et al. 23 described a series of 17 patients with B-precursor ALL in whom Guthrie cards were analyzed with very similar methods and inclusion criteria. Both data sets were combined to analyze the association of positive Guthrie cards and patient characteristics with more statistical power. The combined group included 49 patients and positive screening cards were found in 31 (63%) cases. Positive screening cards were not significantly associated with sex or WBC count at diagnosis, nor maternal age when the patients were born. Preleukemic clones were almost invariably found in patients with hyperdiploid ALL (10/11; 91%), which was significantly higher than in non-hyperdiploid ALL (P ¼ 0.04).
Interestingly, positive screening cards were strongly associated with lower birth weight in our cohort of patients analyzed from both centers (P ¼ 0.01) (Figure 3 ). In each of the 12 patients with a birth weight of p3000 g, preleukemic cells were detected on the Guthrie card. High birth weight has been identified as a risk factor for childhood ALL (reviewed by Tower et al.
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). Largefor-gestational-age infants have higher levels of insulin-like growth factor (IGF)-I which may contribute to the elevated leukemia risk in these children. 38 Because our findings of leukemic clones in lower birth weight patients are in contrast to the large-for-gestational age infant findings, we suggest the following hypothesis: IGF-I or other growth factors stimulate the proliferation and persistence of preleukemic cell clones. Because of a potential greater growth stimulation in large-forgestational-age infants, very small preleukemic cell clone populations can persist and later develop into overt leukemia. ? Figure 2 Percentage of patients with preleukemic cells on Guthrie card. The higher the sensitivity of detecting preleukemic cells, the higher the percentage of positive Guthrie cards. It is very likely that there are some patients in whom preleukemic cells are present at birth, but in a proportion of less than 1/10 000 and therefore not detectable. As a consequence, the percentage of acute lymphoblastic leukemia (ALL) patients with preleukemic cells at birth may be closer to 100%.
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We may have failed to detect the preleukemic cell clones in some of these patients that were present at a very low level at birth. Because of the lower growth stimulation in small-forgestational-age infants, only large preleukemic cell clone populations can persist, which we were able to detect in the Guthrie cards of the lower birth weight patients in our study.
Conclusions
Our results confirm in the largest group of samples analyzed, that the majority of childhood B-precursor ALL arise prior to birth. This was previously shown for subtypes of ALL with specific translocations, but not for B-precursor ALL in general. This indicates that the search for causes of childhood leukemia and potential methods of prevention should concentrate on both prenatal as well as postnatal factors. This suggests that childhood ALL is a potentially screenable disease. However, prospective screening would require a method of detecting preleukemic cells without the knowledge of immunophenotype or IgH gene rearrangement. This has been demonstrated for the t(12;21)-associated ALL translocation using cord blood samples. 39 On the basis of the presence of preleukemic cells in blood samples at birth, the commercial marketing of cord blood collection for healthy newborns, as a potential source of stem cells to be used in the future for a stem cell transplant if a child develops leukemia, would appear to be a potentially poor choice.
